血清肌酐估算的增强肾清除与重型创伤性脑损伤后显著体重下降相关
该回顾性观察队列纳入2015-2024年单中心三级学术I级创伤中心ICU收治的342例重型TBI成人患者,eARC定义为伤后28天内至少一个时间点估算肌酐清除率≥130 mL/min/1.73 m2。eARC发生率为57.6%(197例),eARC组患者更年轻、男性更多、入院GCS更低。eARC组第28天体重下降幅度显著大于非eARC组(中位-12.7% vs 0.0%,p<0.001),严重体重下降更常见;校正年龄和入院GCS后eARC仍与严重体重下降相关。作者结论为假设生成性,eARC可能识别代谢脆弱亚组,但需前瞻性研究用实测肌酐清除率、详细水钠平衡评估和直接体成分测量验证。
要点
- 重型TBI成人ICU患者中eARC(eCrCl≥130 mL/min/1.73 m2)发生率为57.6%(197/342)。
- eARC组第28天体重下降中位-12.7%,非eARC组0.0%(p<0.001),严重体重下降在eARC组更常见。
- 校正年龄和入院GCS后,eARC仍与第28天严重体重下降相关(探索性多变量分析)。
- eARC组更年轻、男性更多、入院GCS更低,提示其或反映高动力/代谢脆弱表型。
- 丙泊酚来源热量、血钠、液体入量、尿量及入量减尿量液体平衡估计均未清楚解释组间体重下降差异。
适用人群与场景
- 2015-2024年单中心三级学术I级创伤中心ICU收治的成人重型创伤性脑损伤(TBI)患者,共342例入院。
诊断标准与关键阈值
- eARC定义为伤后28天内至少一个可获取的eCrCl时间点估算肌酐清除率(eCrCl)≥130 mL/min/1.73 m2。
- 因实测尿肌酐清除率未系统获取,采用血清肌酐估算的肌酐清除率(eCrCl)替代。
处置流程与药物剂量
- 原文未提及
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 研究类型:回顾性观察队列研究;单中心三级学术I级创伤中心;2015-2024年;342例ICU入院。
- eARC发生率为57.6%(197/342);eARC组更年轻、男性更多、入院GCS更低。
- eARC组第28天体重下降中位-12.7%,非eARC组0.0%(p<0.001);严重体重下降在eARC组更频繁。
- 校正年龄和入院GCS的探索性多变量分析中,eARC仍与第28天严重体重下降相关。
- 纳入丙泊酚来源热量后,eARC与非eARC组总能量供给相似;血钠、液体入量、尿量及入量减尿量液体平衡估计未见可解释体重下降差异的组间差异。
证据类型、等级与局限
- 证据类型:回顾性观察队列研究(单中心)。
- 局限:回顾性设计、单中心、样本量342例;eARC基于血清肌酐估算而非实测尿肌酐清除率;作者声明为假设生成性,需前瞻性研究验证。
对床旁实践的改变
- 对重型TBI成人患者,可考虑关注eCrCl≥130 mL/min/1.73 m2的eARC现象(发生率57.6%),并警惕其与第28天显著体重下降(中位-12.7%)的关联。
- 原文结果不能确立eARC为常规监测或干预指征;作者强调需前瞻性研究用实测肌酐清除率、详细水钠平衡和直接体成分测量验证。
- 原文未提及基于eARC的具体营养或液体管理调整方案,不能由本文推出改变现行做法。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND/OBJECTIVE: Augmented renal clearance is commonly evaluated as a pharmacokinetic problem in critically ill trauma patients. In severe traumatic brain injury (TBI), increased serum-creatinine-estimated creatinine clearance may also reflect a broader hyperdynamic or metabolically vulnerable phenotype. We aimed to characterize the incidence and clinical profile of serum-creatinine-estimated augmented renal clearance (eARC) after severe TBI and to examine its association with day-28 body weight loss.
METHODS: We performed a retrospective observational cohort study of intensive care unit (ICU) admissions of adults with severe traumatic brain injury (TBI) at a tertiary academic level I trauma center between 2015 and 2024. Because measured urinary creatinine clearance was not systematically available, serum-creatinine-estimated augmented renal clearance (eARC) was defined as estimated creatinine clearance (eCrCl) ≥ 130 mL/min/1.73 m2 at one or more available eCrCl time points during the first 28 days after injury. Covariate selection was guided by a directed acyclic graph. Additional sensitivity analyses incorporated propofol-derived calories, sodium variables, fluid input, urine output, and the input-minus-urine fluid balance estimate.
RESULTS: Among 342 included admissions, eARC occurred in 197 patients (57.6%). Patients with eARC were younger, more often male, and had lower admission Glasgow Coma Scale (GCS) scores. Patients with eARC experienced greater day-28 body weight loss than non-eARC patients (median -12.7% vs. 0.0%; p < 0.001), and severe weight loss was more frequent in the eARC group. In exploratory multivariable analysis adjusted for age and admission GCS score, eARC remained associated with severe day-28 weight loss. After incorporating propofol-derived calories, total energy delivery was similar between eARC and non-eARC groups. Serum sodium, fluid input, urine output, and the input-minus-urine fluid balance estimate did not show clear group-level differences that explained the observed weight-loss difference.
CONCLUSIONS: Serum-creatinine-estimated augmented renal clearance (ARC) was common after severe TBI and was associated with marked day-28 weight loss. These findings are hypothesis generating and suggest that eARC may identify a metabolically vulnerable subgroup, but prospective studies using measured creatinine clearance, detailed sodium-water balance assessment, and direct body composition measures are needed.
参考来源
- Oda K, Nedelcu R, Abouassaly M, et al. Serum-Creatinine-Estimated Augmented Renal Clearance is Associated with Marked Weight Loss after Severe Traumatic Brain Injury. Neurocrit Care. 2026. PMID: 42811241. doi:10.1007/s12028-026-02666-1
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。